OTLK (Outlook Therapeutics) Other Long-Term Liabilities : $5.45 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Outlook Therapeutics Other Long-Term Liabilities?

Outlook Therapeutics's other long-term liabilities for the quarter that ended in Mar. 2025 was $5.45 Mil.

Outlook Therapeutics's quarterly other long-term liabilities declined from Sep. 2024 ($59.10 Mil) to Dec. 2024 ($18.83 Mil) and declined from Dec. 2024 ($18.83 Mil) to Mar. 2025 ($5.45 Mil).

Outlook Therapeutics's annual other long-term liabilities declined from Sep. 2022 ($0.06 Mil) to Sep. 2023 ($0.01 Mil) but then increased from Sep. 2023 ($0.01 Mil) to Sep. 2024 ($59.10 Mil).

Outlook Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for Outlook Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Other Long-Term Liabilities Chart

Outlook Therapeutics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Other Long-Term Liabilities

Get a 7-Day Free Trial

0.07

0.52

0.06

0.01

59.10

Outlook Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long-Term Liabilities	Get a 7-Day Free Trial															139.19	87.95	59.10	18.83	5.45

Outlook Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Outlook Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (NAS:OTLK) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

41O:Germany

Address

111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Executives

Lawrence A Kenyon	officer: CFO and Secretary	C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Yezan Munther Haddadin	director	ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA, 4TH FLOOR, PO BOX 142904, AMMAN M2 11844
Jeff Evanson	officer: Chief Commercial Officer	C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Terry Dagnon	officer: Chief Operating Officer	C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Faisal Ghiath Sukhtian	director	7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909, AMMAN M2 11844
Kurt J Hilzinger	director	1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Julia A Haller	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Trenary C Russell Iii	director, officer: CEO and President	1700 E ST ANDREW PLACE, SANTA ANA CA 92705
Ghiath M. Sukhtian	director, 10 percent owner	7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BUILDING, 4TH FLOOR, AMMAN M2 11844
Syntone Ventures Llc	10 percent owner	1517 CHAMPLAIN CREST WAY, CARY NC 27513
Randy H Thurman	director	222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Andong Huang	director	C/O OUTLOOK THERAPEUTICS, INC., 4260 US ROUTE 1, MONMOUTH JUNCTION NJ 08852
Gerd Auffarth	director	C/O PRESBIA PLC, 120/121 BAGGOT STREET LOWER, DUBLIN 2 L2 00000
Julian S Gangolli	director	4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Gms Ventures & Investments	director	C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD., 190 ELGIN AVENUE, GEORGE TOWN E9 KYI-9007